Cargando…
Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900506/ https://www.ncbi.nlm.nih.gov/pubmed/20336156 http://dx.doi.org/10.1038/gt.2010.27 |
_version_ | 1782183625383477248 |
---|---|
author | Zeltner, Nadja Kohlbrenner, Erik Clément, Nathalie Weber, Thomas Linden, R. Michael |
author_facet | Zeltner, Nadja Kohlbrenner, Erik Clément, Nathalie Weber, Thomas Linden, R. Michael |
author_sort | Zeltner, Nadja |
collection | PubMed |
description | Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a “ceiling” for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and more strikingly only approximately one of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy. |
format | Text |
id | pubmed-2900506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
record_format | MEDLINE/PubMed |
spelling | pubmed-29005062011-01-01 Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors Zeltner, Nadja Kohlbrenner, Erik Clément, Nathalie Weber, Thomas Linden, R. Michael Gene Ther Article Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a “ceiling” for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and more strikingly only approximately one of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy. 2010-03-25 2010-07 /pmc/articles/PMC2900506/ /pubmed/20336156 http://dx.doi.org/10.1038/gt.2010.27 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Zeltner, Nadja Kohlbrenner, Erik Clément, Nathalie Weber, Thomas Linden, R. Michael Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title | Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title_full | Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title_fullStr | Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title_full_unstemmed | Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title_short | Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors |
title_sort | near-perfect infectivity of wild-type aav as benchmark for infectivity of recombinant aav vectors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900506/ https://www.ncbi.nlm.nih.gov/pubmed/20336156 http://dx.doi.org/10.1038/gt.2010.27 |
work_keys_str_mv | AT zeltnernadja nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors AT kohlbrennererik nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors AT clementnathalie nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors AT weberthomas nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors AT lindenrmichael nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors |